NEW YORK, Sept 30 (Reuters) - U.S. health regulators on Thursday delayed approval of Teva Pharmaceutical Industries Ltd’s (TEVA.O) (TEVA.TA) biotechnology medicine to boost white blood cells that is similar to Amgen Inc’s (AMGN.O) big-selling Neupogen.
